Immune System News and Research

RSS

Researchers invent zinc-stapled insulin to reduce insulin-related cancer risk

For millions of Americans with Type-2 diabetes and inject insulin to control diabetes (with onset typically in adulthood) the associated risk of cancer is of increasing concern. Studies have demonstrated that obesity and excess insulin - whether naturally produced by the body or injected in synthetic form - are associated with an increased incidence of some common cancers.

13 Apr 2010

CSL Behring calls for grant requests through LEAD program

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

13 Apr 2010

Drug boosting production of immune system protein worsens TB

An experimental drug that boosts production of the immune system protein interferon worsens tuberculosis (TB) in mice, according to scientists from the National Institutes of Health. The drug acts indirectly by drawing certain immune cells, in which Mycobacterium tuberculosis (M.tb) bacteria thrive, to the lungs. The findings may have potential implications for the care of people infected with TB, the authors note. The research is reported in the May 3 issue of Journal of Clinical Investigation, now available online.

13 Apr 2010

Oragenics signs distribution agreement with RICCI PHARMA

Florida-based biotechnology company Oragenics, Inc., and RICCI PHARMA, a recognized health products company with offices in Rome and Slovakia, have entered into a distribution agreement that the parties anticipate will provide Oragenics' proprietary oral care probiotic products, EvoraPlus® and EvoraKidsTM, to RICCI PHARMA. RICCI PHARMA will have exclusive distribution rights through Duc in Altum, a foundation whose humanitarian projects are inspired by the social teachings of the late Pope John Paul II.

13 Apr 2010

IDF awarded NIH grant for advancing knowledge in PIDD through continuance of USIDNET program

The Immune Deficiency Foundation (IDF) is pleased to announce that it has been awarded the grant "Resources to Assist Investigations in Primary Immunodeficiency Diseases" from the National Institutes of Health (NIH). This grant will allow IDF to continue to advance the detection, understanding, diagnosis and treatment of primary immunodeficiency diseases (PIDD) through their program, the United States Immunodeficiency Network (USIDNET).

13 Apr 2010

Stem cell scientists receive stimulus grants to study lung and blood disorders

Stem cell scientists at The University of Texas Health Science Center at Houston (UTHealth) were awarded stimulus grants totaling almost $2 million to research experimental treatments for blood disorders and inherited lung diseases affecting children.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Dangers of BPA: South Florida children need protection

Something must be done to protect the children of South Florida from this dangerous chemical says one student ready to bring the facts to the Broward County Commission. The government's recent announcement that the EPA is considering the addition of Bisphenol-A (BPA) to their list of "Chemicals of Concern," is a step in the right direction, but long overdue, according to high school junior and BPA researcher, Wendi Oppenheim.

12 Apr 2010

BeaconEquity.com releases investment report on Cord Blood America

BeaconEquity.com announces an investment report featuring umbilical cord blood stem cell preservation company Cord Blood America. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Apr 2010

Gene playing crucial role in immune system balance identified

A team led by St. Jude researchers identified a gene pivotal for immune system balance. Ultimately, the discovery may aid efforts to tame allergies and asthma.

12 Apr 2010

S. thermophilus CRL 1190-fermented milk effective in therapeutic treatment of chronic gastritis: Research

Gastritis produced by acetyl-salicylic acid consumption is a common disorder worldwide. The use of probiotics has been proposed to ameliorate different gastrointestinal tract diseases such as inflammatory bowel disease, diarrhea, irritable bowel syndrome, etc. However, little attention has been paid to the use of probiotics in gastric disease.

12 Apr 2010

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

MaxCyte, Inc., and Medinet Co. Ltd., announced today that they have agreed to amend their License, Development and Supply Agreement for expansion of Medinet's right to use MaxCyte's cell loading technology in Asia Pacific markets.

9 Apr 2010

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company and its collaborators from Drexel University, Cheyney University, and the University of Pennsylvania have received a $2.8 million grant to develop a DNA vaccine to treat hepatitis C virus.

9 Apr 2010

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

Ultraviolet light -- a culprit behind sunburns, wrinkles and skin cancer -- offers benefits for some skin conditions, according to the April issue of Mayo Clinic Health Letter.

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

9 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

Immune System News and Research

Researchers invent zinc-stapled insulin to reduce insulin-related cancer risk

CSL Behring calls for grant requests through LEAD program

Drug boosting production of immune system protein worsens TB

Oragenics signs distribution agreement with RICCI PHARMA

IDF awarded NIH grant for advancing knowledge in PIDD through continuance of USIDNET program

Stem cell scientists receive stimulus grants to study lung and blood disorders

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Dangers of BPA: South Florida children need protection

BeaconEquity.com releases investment report on Cord Blood America

Gene playing crucial role in immune system balance identified

S. thermophilus CRL 1190-fermented milk effective in therapeutic treatment of chronic gastritis: Research

MaxCyte, Medinet agree to amend License, Development and Supply Agreement

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Mayo Clinic Health Letter: UV light slows skin cell overgrowth, alters immune system

"Nanovaccine" reverses diabetes

Nanotechnology-based vaccine cures mice with type 1 diabetes

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Immunology eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News